Can sporadic medullary thyroid carcinoma be biochemically predicted? Prospective analysis of 66 operated patients with elevated serum calcitonin levels

World Journal of Surgery

Volumn 26, Issue 8, 2002, Pages 886-890

  Iacobone, Maurizio ^a   Niccoli Sire, Patricia ^a   Sebag, Frederic ^a   De Micco, Catherine ^a   Henry, Jean François ^a  

^a TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; DIAGNOSTIC AGENT; PENTAGASTRIN; TUMOR MARKER;

ADULT; AGED; CALCITONIN BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; THYROID HYPERPLASIA; THYROID MEDULLARY CARCINOMA; THYROID PARAFOLLICULAR CELL; THYROIDECTOMY; TREATMENT INDICATION; ADOLESCENT; ARTICLE; BLOOD; DIFFERENTIAL DIAGNOSIS; HYPERPLASIA; MEDULLARY CARCINOMA; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; THYROID DISEASE; THYROID GLAND; THYROID TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CALCITONIN; CARCINOMA, MEDULLARY; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; HYPERPLASIA; MALE; MIDDLE AGED; PENTAGASTRIN; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; THYROID DISEASES; THYROID GLAND; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0036691183     PISSN: 03642313     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00268-002-6613-0     Document Type: Conference Paper

References (24)

1. Wells SA, Franz C. Medullary carcinoma of the thyroid gland. World J. Surg. 2000;24:952-956
2. Henry JF, Denizot A, Puccini M, et al. Latent subclinical medullary thyroid carcinoma: diagnosis and treatment. World J. Surg. 1998;22:752-756
3. Pacini F, Fontanelli M, Fugazzola L, et al. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 1994;78:826-829
4. Rieu M, Lame MC, Richard A, et al. Prevalence of sporadic medullary thyroid carcinoma: the importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules. Clin. Endocrinol. (Oxf.) 1995;42:453-460
5. Niccoli P, Wion-Barbot N, Caron P, et al. Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. J. Clin. Endocrinol. Metab. 1997;82:338-341
6. Niccoli P, Conte Devolx B, Lejeune PJ, et al. Les hypercalcitoninémies en dehors des cancers médullaires de la thyroïde. Ann. Endocrinol. (Paris) 1996;57:15-21
7. Vierhapper H, Raber W, Bieglmayer C, et al. Routine measurement of plasma calcitonin in nodular thyroid diseases. J. Clin. Endocrinol. Metab. 1997;82:1589-1593
8. Guyetant S, Wion-Barbot N, Rousselet MC, et al. C-cell hyperplasia associated with chronic lymphocytic thyroiditis: a retrospective quantitative study of 112 cases. Hum. Pathol. 1994;25:514-521
9. Albores-Saavedra J, Monforte H, Nadji M, et al. C-cell hyperplasia in thyroid tissue adjacent to follicular cell tumors. Hum. Pathol. 1988;19:795-799
10. Montesco MC, Pinarello A, Ninfo V. Parafollicular C-cell hyperplasia: report of three cases in primary thyroid lymphomas. Tumori 1988;74:97-100
11. Biddinger PW, Brennan MF, Rosen PP. Symptomatic C-cell hyperplasia associated with chronic lymphocytic thyroiditis. Am. J. Surg. Pathol. 1991;15:599-604
12. Barbot N, Calmettes C, Schuffenecker I, et al. Pentagastrin stimulation test and early diagnosis of medullary thyroid carcinoma using an immunoradiometric assay of calcitonin: comparison with genetic screening in hereditary medullary thyroid carcinoma. J. Clin. Endocrinol. Metab, 1994;78:114-120
13. Wion-Barbot N, Schuffenecker I, Niccoli P, et al. Results of the calcitonin stimulation test in normal volunteers compared with genetically unaffected members of MEN 2A and familial medullary thyroid carcinoma families. Ann. Endocrinol. (Paris) 1997;8:302-308
14. Sobin LH, Wittekind C. TNM Classification of Malignant Tumors, New York, Wiley, 1997
15. Modigliani E, Cohen R, Campos JM, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. Clin. Endocrinol. (Oxf.) 1998;48:265-273
16. Kebebew E, Ituarte PH, Siperstein AE, et al. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 2000;88:1139-1148
17. Baudin E, Bidart JM, Rougier P, et al. Screening for multiple endocrine neoplasia type 1 and hormonal production in apparently sporadic neuroendocrine tumours. J. Clin. Endocrinol. Metab. 1999;84:69-75
18. Machens A, Haedecke J, Holzhausen HJ, et al. Differential diagnosis of calcitonin-secreting neuroendocrine carcinoma of the foregut by pentagastrin stimulation. Langenbecks Arch. Surg. 2000;385:398-401
19. Niccoli P, Brunet P, Roubicek C, et al. Abnormal calcitonin basal levels and pentagastrin response in patients with chronic renal failure on maintenance hemodialysis. Eur. J. Endocrinol. 1995;132:75-81
20. Leboulleux S, Baudin E, Young J, et al. Gastroenteropancreatic neuroendocrine tumor metastases to the thyroid gland: differential diagnosis with medullary thyroid carcinoma. Eur. J. Endocrinol. 1999;140:187-191
21. McLeod MK, Vinik AI. Calcitonin immunoreactivity and hypercalcitoninemia in two patients with sporadic, nonfamilial, gastroenteropancreatic neuroendocrine tumors. Surgery 1992;111:484-488
22. Li Volsi VA. C cell hyperplasia/neoplasia. J. Clin. Endocrinol. Metab. 1997;82:39-41
23. saint André JP, Guyetant S. Hypercalcitoninemies non tumorales: anathomie pathologique. Ann. Endocrinol. (Paris) 1996;57:23-44
24. Guilloteau D, Perdrisot D, Calmettes C, et al. Diagnosis of medullary carcinoma of the thyroid by calcitonin assay using monoclonal antibodies. J. Clin. Endocrinol. Metab. 1990;71:1064-1067